- Home
- MX vs CHRS Comparison
MX vs CHRS Comparison
Compare MX & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MX | CHRS |
|---|---|---|
| Founded | 2003 | 2010 |
| Country | South Korea | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 179.7M | 159.1M |
| IPO Year | 2007 | 2014 |
Fundamental Metrics
Financial Performance| Metric | MX | CHRS |
|---|---|---|
| Price | $2.38 | $0.83 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $7.75 |
| AVG Volume (30 Days) | 758.5K | ★ 1.5M |
| Earning Date | 11-04-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 43.06 | ★ 472.00 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $178,860,000.00 | N/A |
| Revenue This Year | $5.39 | $44.19 |
| Revenue Next Year | $6.37 | $65.06 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.18 | $0.81 |
| 52 Week High | $9.86 | $2.62 |
Technical Indicators
Market Signals| Indicator | MX | CHRS |
|---|---|---|
| Relative Strength Index (RSI) | 34.33 | 34.86 |
| Support Level | N/A | N/A |
| Resistance Level | $3.06 | $1.53 |
| Average True Range (ATR) | 0.13 | 0.09 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 3.63 | 11.78 |
Price Performance
Historical ComparisonAbout MX Magnachip Semiconductor Corporation
MagnaChip Semiconductor Corp designs and manufactures analog and mixed-signal semiconductor platform solutions for communications, Internet of Things applications, consumer, industrial and automotive applications. The company's product portfolio consists of large display solutions, mobile display solutions, sensor solutions, LED solutions, mobile solutions, and power conversions. The Company operates within a single operating segment, Power Solutions business. The company operates in Korea, Asia Pacific (other than Korea), United States and Europe.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.